Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 6
2011 2
2012 1
2013 8
2014 6
2015 5
2016 3
2017 9
2018 11
2019 20
2020 28
2021 40
2022 51
2023 48
2024 45
2025 66
2026 47

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Results by year

Filters applied: . Clear all
Page 1
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Disease and Injury and Risk Factor Collaborators. GBD 2023 Disease and Injury and Risk Factor Collaborators. Lancet. 2025 Oct 18;406(10513):1873-1922. doi: 10.1016/S0140-6736(25)01637-X. Epub 2025 Oct 12. Lancet. 2025. PMID: 41092926 Free PMC article.
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial.
Tian F, Dai H, Sha D, Yu Y, Jing H, Sun C, Shang L, Liu Y, Feng R, Li J, Liu H, Chen Y, Shi Y, Wang J, Zhuo H, Zhang X, Lian G, Chong W, Chen H, Yang Z, Li L, Jing C. Tian F, et al. Among authors: liu y. Lancet Oncol. 2025 Aug;26(8):1043-1054. doi: 10.1016/S1470-2045(25)00286-4. Epub 2025 Jul 8. Lancet Oncol. 2025. PMID: 40645192 Clinical Trial.
CRISPR/LbCas12a-Mediated Genome Editing in Soybean.
Liang D, Liu Y, Li C, Wen Q, Xu J, Geng L, Liu C, Jin H, Gao Y, Zhong H, Dawson J, Tian B, Barco B, Su X, Dong S, Li C, Elumalai S, Que Q, Jepson I, Shi L. Liang D, et al. Among authors: liu y. Methods Mol Biol. 2023;2653:39-52. doi: 10.1007/978-1-0716-3131-7_3. Methods Mol Biol. 2023. PMID: 36995618
361 results